
KIM FOREST — Investor Relations & Filings
Kim Forest Enterprise Co., Ltd. specializes in precision medicine and molecular diagnostics, providing integrated solutions for clinical research and healthcare. The company offers a "One Stop Solution" encompassing experimental consultation, laboratory equipment supply, and bioinformatics analysis. Key products and services include Next-Generation Sequencing (NGS), PCR systems, ELISA readers, and high-content imaging systems. The company focuses on genetic testing for cancer screening, hereditary diseases, and personalized health management. By synthesizing genomic data with clinical insights, Kim Forest facilitates biomarker identification and the development of optimized treatment strategies. Its portfolio also extends to customized enzymes, drug screening technologies, and precision nutrition, supporting the advancement of personalized medicine through comprehensive technical expertise and reliable diagnostic reporting.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年第1季財務報告書 — 202601_6645_AI1.pdf | 2026-05-11 | Chinese | |
| 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | |
| 115年04月董事會成員及持股 | 2026-05-05 | Chinese | |
| 公告本公司115年第一季財務報告董事會 預計召開日期為115年05月08日 | 2026-04-30 | Chinese | |
| 114年第4季財務報告書 — 202504_6645_AIC.pdf | 2026-04-21 | Chinese | |
| 114年第4季財務報告書 — 202504_6645_AIA.pdf | 2026-04-21 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45580484 | 115年第1季財務報告書 — 202601_6645_AI1.pdf | 2026-05-11 | Chinese | ||
| 41459706 | 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | ||
| 41457341 | 115年04月董事會成員及持股 | 2026-05-05 | Chinese | ||
| 39887117 | 公告本公司115年第一季財務報告董事會 預計召開日期為115年05月08日 | 2026-04-30 | Chinese | ||
| 34695803 | 114年第4季財務報告書 — 202504_6645_AIC.pdf | 2026-04-21 | Chinese | ||
| 34695802 | 114年第4季財務報告書 — 202504_6645_AIA.pdf | 2026-04-21 | Chinese | ||
| 34695801 | 114年第4季財務報告書 — 202504_6645_AI3.pdf | 2026-04-21 | Chinese | ||
| 34695800 | 114年第4季財務報告書 — 202504_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34695799 | 114年第4季財務報告書 — 202503_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34695798 | 114年第4季財務報告書 — 202502_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34695797 | 114年第4季財務報告書 — 202501_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34690456 | 114年年報及股東會資料 — 2026_6645_20260522F17.pdf | 2026-04-20 | Chinese | ||
| 34690455 | 114年年報及股東會資料 — 2025_6645_20260522FE4.pdf | 2026-04-20 | English | ||
| 34690454 | 114年年報及股東會資料 — 2025_6645_20260522F04.pdf | 2026-04-20 | Chinese | ||
| 34690442 | 114年年報及股東會資料 — 2026_6645_20260522F02.pdf | 2026-04-20 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Predict S.p.A.
Develops and distributes AI medical solutions for imaging, …
|
PRE | IT | Professional, scientific and te… |
|
PRESCIENT THERAPEUTICS LIMITED
Clinical-stage oncology firm developing modular cell therap…
|
PTX | AU | Professional, scientific and te… |
|
PreveCeutical Medical
Health sciences company researching and developing innovati…
|
PREV | CA | Professional, scientific and te… |
|
ProMIS Neurosciences Inc.
Develops selective antibody therapeutics for neurodegenerat…
|
PMN | CA | Professional, scientific and te… |
|
Propanc Biopharma, Inc.
Clinical-stage company developing cancer treatments to prev…
|
PPCB | US | Professional, scientific and te… |
|
ProQR Therapeutics N.V.
Develops RNA therapies for severe genetic disorders using i…
|
PRQR | NL | Professional, scientific and te… |
|
Prostatype Genomics AB
Develops a genetic test that assesses prostate cancer aggre…
|
PROGEN | SE | Professional, scientific and te… |
|
Protagenic Therapeutics, Inc.\new
Develops peptide-based therapeutics for stress-related neur…
|
PTIX | US | Professional, scientific and te… |
|
Protara Therapeutics, Inc.
Clinical-stage biopharma developing therapies for cancer an…
|
TARA | US | Professional, scientific and te… |
|
PROTEINA CO.,LTD.
A biotech firm analyzing protein interactions for drug and …
|
468530 | KR | Professional, scientific and te… |
KIM FOREST via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52599/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52599 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52599 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52599 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52599}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for KIM FOREST (id: 52599)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.